Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | BAX | Q07812 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187457 | 0.85 | HSD17B1 (0.54) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL7776861 | 0.83 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL12717371 | 0.83 | FFAR1 (0.49) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL20244667 | 0.81 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL14727899 | 0.81 | HPGD (0.49) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL11338721 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL8164406 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1NPC1HPGDLMNA | |
| SCHEMBL10187443 | 0.80 | PARP10 (0.48) | SMN1; SMN2ALDH1A1RAB9AHPGDPARP10 | |
| SCHEMBL10238688 | 0.79 | KDM4E (0.53) | SMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL28861673 | 0.77 | HPGD (0.55) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-20 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-7144917-B2 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006125208-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20040127478-A1 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY | 2004-07-01 | — | — | US | disclosed |
| US-6703415-B2 | EPOXIDES OR THIIRANE DERIVATIVES; TREATING OR PREVENTING CANCER, ANGIOGENESIS, ARTHRITIS, CONNECTIVE TISSUE DISEASE, CARDIOVASCULAR DISEASE, INFLAMMATION OR AUTOIMMUNE DISEASE; ANTIFERTILITY AGENTS | WAYNE STATE UNIVERSITY | 2004-03-09 | — | — | US | disclosed |
| US-6583299-B1 | Matrix metalloprotease inhibitors; nonsuppression of tumor necrosis factor production | G.D. SEARLE & CO. | 2003-06-24 | — | — | US | disclosed |
| EP-1309579-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | UNITED STATES GOVERNMENT SECRETARY OF THE ARMY, THE | 2002-03-28 | — | — | US | disclosed |
| WO-2001092244-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | MMP12, MMP1, MMP3 | SMN1; SMN2 4200/4885ALDH1A1 1067/4885NPC1 4029/4885 |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | SMN1; SMN2 2133/4885ALDH1A1 333/4885NPC1 1457/4885 |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | MMP9, MMP10, MMP17 | SMN1; SMN2 116/4885ALDH1A1 288/4885NPC1 549/4885 |
| US-20040127478-A1 | Inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | SMN1; SMN2 4306/4885ALDH1A1 1774/4885NPC1 3944/4885 |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | MMP9, MMP1, MMP2 | SMN1; SMN2 1825/4885ALDH1A1 403/4885NPC1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.